Clinical Trials Directory

Trials / Completed

CompletedNCT01831661

Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fasting Condition

A Randomized, Open Label, Two-treatment, Two -Period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg of Ipca Laboratories Ltd, India and GLUCOPHAGE®XR (Metformin HCl Extended-release Tablets) 750 mg of Bristol-Myers Squibb Company, USA in Normal, Healthy, Adult, Human Subjects Under Fasting Condition

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
48 (actual)
Sponsor
IPCA Laboratories Ltd. · Industry
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

The study was a randomized, open label, two-treatment, two-period, two-sequence, single dose, crossover, oral bioequivalence study in normal, healthy adult human subjects under fasting condition.

Detailed description

Objective of the study is to compare and evaluate the single-dose oral bioavailability of Metformin Hydrochloride Extended-Release Tablets USP 750 mg of Ipca Laboratories Ltd, India and GLUCOPHAGE®XR (Metformin HCl extended-release tablets) 750 mg of Bristol-Myers Squibb Company, USA in normal, healthy, adult, human subjects under fasting condition. Total duration of the study was of 17 days from the day of admission of first period till the end of second period. Upon entering into the study, subjects were housed in clinical facility of Veeda Clinical Research Pvt. Ltd. to ensure 10 hours overnight fasting before dosing and continued to be housed in the facility till 36.00 hours post-dose blood sample collection in each of the two periods. A gap of 14 days was kept as wash out between each consecutive dosing period.

Conditions

Interventions

TypeNameDescription
DRUGMetformin Hydrochloride Extended-Release Tablets USP 750 mgMetformin Hydrochloride Extended-Release Tablets 750 mg once a day
DRUGGLUCOPHAGE®XRGLUCOPHAGE®XR 750 mg once a day

Timeline

Start date
2012-12-01
Primary completion
2012-12-01
Completion
2013-02-01
First posted
2013-04-15
Last updated
2013-04-15

Locations

1 site across 1 country: India

Source: ClinicalTrials.gov record NCT01831661. Inclusion in this directory is not an endorsement.